ArticleJNCI cancer spectrum2020
Germline Testing for Patients With
Article in JNCI cancer spectrum, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Pathological features of BRCA-mutated breast cancer in Shenzhen, China: a single-center study.PeerJ · 2026Article
- Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board.The oncologist · 2023Article
- Case report: olaparib use in metastatic lung adenocarcinoma withCold Spring Harbor molecular case studies · 2022Article
- Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Preoperational diagnosis and management of breast ductal carcinomaWorld journal of clinical cases · 2022Article
- PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.Cancers · 2022Review
- Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study.Cancers · 2021Article
- The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?Journal of the National Comprehensive Cancer Network : JNCCN · 2021Review
- Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation.Cancers · 2021Article
- Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.Cancer reports (Hoboken, N.J.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe National Comprehensive Cancer Network (NCCN) recommends germline testing for pathogenic
methodsWe retrospectively collected all Stanford patients with
resultsOf 164 participants, 51 (31.1%) had no recommendation for germline testing. Of the 97 available germline-testing results, 54 (55.7%) were positive for pathogenic
conclusionsOur study highlights the importance of provider education outside of the oncologic specialties typically associated with
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.